Retour

Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update

Calendar Calendar of Events

The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.

GlobeNewswire Inc. • 07/05/2024 à 14:00:00
Biora Therapeutics, Inc. Common Stock
Address: 4330 LA JOLLA VILLAGE DRIVE
Postal Code: 92122
City: SAN DIEGO
State: CA
Phone Number: 855-293-2639
Website: https://www.bioratherapeutics.com
Status: Active
Company Info

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.

List Date2020-06-19
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001580063
Composite figiBBG007K8X5S6
Share Class figiBBG007K8X5T5
Market Cap26,184,440 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees58
Share Class Shares Outstanding35880000
Weighted Shares Outstanding35883843
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
0.734
0.728
0.75
0.73
0.732
Variance
1.1%
-1.62%
1.63%
-0.41%
-1.08%
Open
0.726
0.74
0.738
0.733
0.74
Highest
0.745
0.744
0.758
0.746
0.75
Lowest
0.745
0.743
0.758
0.746
0.749
History
PeriodVarhighestlowest
1 week
-0.81%
0.75
0.743
1 month
18.2%
0.621
0.618
3 month
-9.38%
0.888
0.618
6 month
-46.42%
1.385
0.618
1 year
-79.03%
3.75
0.618
3 year
-96.59%
22.2475
0.618
5 year
-96.59%
22.2475
0.618
10 year
-96.59%
22.2475
0.618
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-14 2023-11-13 UNPUB
Assets 53,243,000 49,673,000 34,703,000 UNPUB
Current Assets 37,168,000 33,885,000 19,247,000 UNPUB
Current Liabilities 25,083,000 37,668,000 69,544,000 UNPUB
Equity -104,998,000 -120,881,000 -118,786,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent -104,998,000 -120,881,000 -118,786,000 UNPUB
Liabilities 158,241,000 170,554,000 153,489,000 UNPUB
Liabilities And Equity 53,243,000 49,673,000 34,703,000 UNPUB
Noncurrent Assets 16,075,000 15,788,000 15,456,000 UNPUB
Noncurrent Liabilities 133,158,000 132,886,000 83,945,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-14 2023-11-13 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -23,000 -4,011,000 -13,883,000 UNPUB
Net Cash Flow, Continuing -23,000 -4,011,000 -13,883,000 UNPUB
Net Cash Flow From Financing Activities 12,081,000 7,630,000 -2,848,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 12,081,000 7,630,000 -2,848,000 UNPUB
Net Cash Flow From Investing Activities -6,000 -19,000 -1,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -6,000 -19,000 -1,000 UNPUB
Net Cash Flow From Operating Activities -12,098,000 -11,622,000 -11,034,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -12,098,000 -11,622,000 -11,034,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-14 2023-11-13 UNPUB
Comprehensive Income/Loss -17,441,000 -17,807,000 -73,454,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -17,441,000 -17,807,000 -73,454,000 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-14 2023-11-13 UNPUB
Basic Earnings Per Share -2 -1 -5 UNPUB
Benefits Costs and Expenses 17,443,000 17,805,000 73,453,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 17,443,000 17,805,000 73,453,000 UNPUB
Diluted Earnings Per Share -2 -1 -5 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -17,441,000 -17,807,000 -73,454,000 UNPUB
Income/Loss From Continuing Operations Before Tax -17,441,000 -17,803,000 -73,453,000 UNPUB
Income Tax Expense/Benefit UNPUB 4,000 1,000 UNPUB
Interest Expense, Operating 2,680,000 2,703,000 2,592,000 UNPUB
Net Income/Loss -17,441,000 -17,807,000 -73,454,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -17,441,000 -17,807,000 -73,454,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -17,441,000 -17,807,000 -73,454,000 UNPUB
Operating Expenses 15,546,000 14,936,000 23,321,000 UNPUB
Operating Income/Loss -15,544,000 -14,934,000 -23,321,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 2,000 2,000 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-15 2022-11-14 2023-03-30
Assets UNPUB 77,101,000 62,614,000 53,525,000
Current Assets UNPUB 60,145,000 46,360,000 38,116,000
Current Liabilities UNPUB 40,584,000 27,391,000 23,305,000
Equity UNPUB -96,106,000 -97,443,000 -102,287,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB -96,106,000 -97,443,000 -102,287,000
Liabilities UNPUB 173,207,000 160,057,000 155,812,000
Liabilities And Equity UNPUB 77,101,000 62,614,000 53,525,000
Noncurrent Assets UNPUB 16,956,000 16,254,000 15,409,000
Noncurrent Liabilities UNPUB 0 132,666,000 132,507,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-15 2022-11-14 2023-03-30
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB -18,728,000 -11,446,000 -57,911,000
Net Cash Flow, Continuing UNPUB -19,212,000 -11,539,000 -59,669,000
Net Cash Flow From Financing Activities UNPUB 1,125,000 -1,477,000 7,298,000
Net Cash Flow From Financing Activities, Continuing UNPUB 1,125,000 -1,477,000 7,298,000
Net Cash Flow From Investing Activities UNPUB -214,000 -164,000 -792,000
Net Cash Flow From Investing Activities, Continuing UNPUB -214,000 -164,000 -792,000
Net Cash Flow From Operating Activities UNPUB -19,639,000 -9,805,000 -64,417,000
Net Cash Flow From Operating Activities, Continuing UNPUB -20,123,000 -9,898,000 -66,175,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-15 2022-11-14 2023-03-30
Comprehensive Income/Loss UNPUB -5,513,000 -5,114,000 -38,157,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -5,513,000 -5,114,000 -38,157,000
Other Comprehensive Income/Loss UNPUB 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-15 2022-11-14 2023-03-30
Basic Earnings Per Share UNPUB -1 -1 -5
Benefits Costs and Expenses UNPUB 6,101,000 14,954,000 61,403,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB 6,101,000 14,954,000 61,403,000
Diluted Earnings Per Share UNPUB -1 -1 -5
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -5,997,000 -14,874,000 -48,830,000
Income/Loss From Continuing Operations Before Tax UNPUB -6,834,000 -14,716,000 -49,250,000
Income Tax Expense/Benefit UNPUB -837,000 158,000 -420,000
Interest Expense, Operating UNPUB 2,772,000 2,773,000 10,990,000
Net Income/Loss UNPUB -5,513,000 -5,114,000 -38,157,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -5,513,000 -5,114,000 -38,157,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -5,513,000 -5,114,000 -38,157,000
Operating Expenses UNPUB 14,314,000 13,967,000 62,086,000
Operating Income/Loss UNPUB -14,210,000 -13,887,000 -61,781,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 104,000 80,000 12,153,000
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:BIOR240517P00004000 OPASPS Put American 100 4 BATO 2024-05-17
O:BIOR240517P00003000 OPASPS Put American 100 3 BATO 2024-05-17
O:BIOR240517P00002000 OPASPS Put American 100 2 BATO 2024-05-17
O:BIOR240517P00001000 OPASPS Put American 100 1 BATO 2024-05-17
O:BIOR240517C00004000 OCASPS Call American 100 4 BATO 2024-05-17
O:BIOR240517C00003000 OCASPS Call American 100 3 BATO 2024-05-17
O:BIOR240517C00002000 OCASPS Call American 100 2 BATO 2024-05-17
O:BIOR240517C00001000 OCASPS Call American 100 1 BATO 2024-05-17
O:BIOR240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:BIOR240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:BIOR240419P00004000 OPASPS Put American 100 4 BATO 2024-04-19
O:BIOR240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:BIOR240419P00001000 OPASPS Put American 100 1 BATO 2024-04-19
O:BIOR240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:BIOR240419C00004000 OCASPS Call American 100 4 BATO 2024-04-19
O:BIOR240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:BIOR240419C00001000 OCASPS Call American 100 1 BATO 2024-04-19
O:BIOR240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:BIOR240315P00004000 OPASPS Put American 100 4 BATO 2024-03-15
O:BIOR240315P00003000 OPASPS Put American 100 3 BATO 2024-03-15
O:BIOR240315P00002000 OPASPS Put American 100 2 BATO 2024-03-15
O:BIOR240315P00001000 OPASPS Put American 100 1 BATO 2024-03-15
O:BIOR240315C00004000 OCASPS Call American 100 4 BATO 2024-03-15
O:BIOR240315C00003000 OCASPS Call American 100 3 BATO 2024-03-15
O:BIOR240315C00002000 OCASPS Call American 100 2 BATO 2024-03-15
O:BIOR240315C00001000 OCASPS Call American 100 1 BATO 2024-03-15
O:BIOR240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:BIOR240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:BIOR240216P00004000 OPASPS Put American 100 4 BATO 2024-02-16
O:BIOR240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:BIOR240216P00001000 OPASPS Put American 100 1 BATO 2024-02-16
O:BIOR240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:BIOR240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:BIOR240216C00004000 OCASPS Call American 100 4 BATO 2024-02-16
O:BIOR240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:BIOR240216C00001000 OCASPS Call American 100 1 BATO 2024-02-16
O:BIOR240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:BIOR240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:BIOR240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:BIOR240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:BIOR240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:BIOR240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:BIOR240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:BIOR240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:BIOR240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:BIOR240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:BIOR1240119P00010000 OPASPN Put American 4 10 BATO 2024-01-19
O:BIOR1240119P00007500 OPASPN Put American 4 7.5 BATO 2024-01-19
O:BIOR1240119P00005500 OPASPN Put American 4 5.5 BATO 2024-01-19
O:BIOR1240119P00005000 OPASPN Put American 4 5 BATO 2024-01-19
O:BIOR1240119P00004500 OPASPN Put American 4 4.5 BATO 2024-01-19
O:BIOR1240119P00004000 OPASPN Put American 4 4 BATO 2024-01-19
O:BIOR1240119P00003500 OPASPN Put American 4 3.5 BATO 2024-01-19
O:BIOR1240119P00003000 OPASPN Put American 4 3 BATO 2024-01-19
O:BIOR1240119P00002500 OPASPN Put American 4 2.5 BATO 2024-01-19
O:BIOR1240119P00002000 OPASPN Put American 4 2 BATO 2024-01-19
O:BIOR1240119P00001500 OPASPN Put American 4 1.5 BATO 2024-01-19
O:BIOR1240119P00001000 OPASPN Put American 4 1 BATO 2024-01-19
O:BIOR1240119P00000500 OPASPN Put American 4 0.5 BATO 2024-01-19
O:BIOR1240119C00010000 OCASPN Call American 4 10 BATO 2024-01-19
O:BIOR1240119C00007500 OCASPN Call American 4 7.5 BATO 2024-01-19
O:BIOR1240119C00005500 OCASPN Call American 4 5.5 BATO 2024-01-19
O:BIOR1240119C00005000 OCASPN Call American 4 5 BATO 2024-01-19
O:BIOR1240119C00004500 OCASPN Call American 4 4.5 BATO 2024-01-19
O:BIOR1240119C00004000 OCASPN Call American 4 4 BATO 2024-01-19
O:BIOR1240119C00003500 OCASPN Call American 4 3.5 BATO 2024-01-19
O:BIOR1240119C00003000 OCASPN Call American 4 3 BATO 2024-01-19
O:BIOR1240119C00002500 OCASPN Call American 4 2.5 BATO 2024-01-19
O:BIOR1240119C00002000 OCASPN Call American 4 2 BATO 2024-01-19
O:BIOR1240119C00001500 OCASPN Call American 4 1.5 BATO 2024-01-19
O:BIOR1240119C00001000 OCASPN Call American 4 1 BATO 2024-01-19
O:BIOR1240119C00000500 OCASPN Call American 4 0.5 BATO 2024-01-19
O:BIOR240119P00004000 OPASPS Put American 100 4 BATO 2024-01-19
O:BIOR240119P00001000 OPASPS Put American 100 1 BATO 2024-01-19
O:BIOR240119C00004000 OCASPS Call American 100 4 BATO 2024-01-19
O:BIOR240119C00001000 OCASPS Call American 100 1 BATO 2024-01-19
O:BIOR231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:BIOR231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:BIOR231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:BIOR231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:BIOR231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:BIOR231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:BIOR231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:BIOR231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:BIOR231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:BIOR231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:BIOR231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:BIOR231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:BIOR231020P00012500 OPASPS Put American 100 12.5 BATO 2023-10-20
O:BIOR231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:BIOR231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:BIOR231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:BIOR231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:BIOR231020C00012500 OCASPS Call American 100 12.5 BATO 2023-10-20
O:BIOR231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:BIOR231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:BIOR231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:BIOR231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:BIOR230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:BIOR230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:BIOR230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:BIOR230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:BIOR230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:BIOR230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:BIOR230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:BIOR230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:BIOR230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:BIOR230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:BIOR230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:BIOR230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:BIOR230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:BIOR230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific.
GlobeNewswire Inc. • 3d ago
Calendar Calendar of Events
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.
GlobeNewswire Inc. • 1w ago
News Clinical Study
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
GlobeNewswire Inc. • 1mo ago
Stocks Financing Agreements
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock and concurrent private placement of unregistered warrants to purchase up to 5,454,548 shares of common stock. The warrants have an exercise price of $1.10 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants, and will expire five years from the date of stockholder approval.
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.
GlobeNewswire Inc. • 1mo ago
stocks Earnings Releases and Operating Results
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.
GlobeNewswire Inc. • 1mo ago
Health Health
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
GlobeNewswire Inc. • 4mo ago
Management Partnerships
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models.
GlobeNewswire Inc. • 5mo ago
News Product / Services Announcement
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon
GlobeNewswire Inc. • 5mo ago
Stocks Earnings Releases and Operating Results
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
NaviCap™ platform advancing toward initiation of phase 1 clinical trial by year end; Pharma collaborations accelerate for the BioJet™ platform
GlobeNewswire Inc. • 6mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT